2025-11-21, 12:09:15 p.m.
November 21, 2025 — AstraZeneca is set to expand its manufacturing presence in Maryland with a $2 billion investment, according to a company press release. The investment includes significant expansion of the company’s biologics manufacturing facility in Frederick and the construction of a new facility in Gaithersburg.
The Frederick facility will nearly double its commercial manufacturing capacity. This expansion will enable an increased supply of existing medicines and, for the first time, will facilitate production across AstraZeneca’s rare disease portfolio. The expansion is expected to create 200 highly skilled jobs and 900 construction roles, with operations beginning in 2029.
AstraZeneca will also construct a new clinical manufacturing facility in Gaithersburg, which will be fully operational by 2029. This new facility is expected to create 100 new jobs, retain 400 existing roles, and support 1,000 construction-related jobs.
Both facilities will utilize advanced technologies, including AI, automation, and data analytics, and adhere to high environmental standards, according to the company.
Maryland Governor Wes Moore said AstraZeneca’s investment affirms the state’s reputation as a global leader in life sciences.
Moore stated that the company’s commitment strengthens the U.S. medicine supply chain, accelerates the development of life-saving therapies, and creates hundreds of jobs.
AstraZeneca Chief Executive Officer Pascal Soriot noted the investment supports 2,600 jobs and brings the company’s rare disease portfolio onshore for the first time.
The announcement is part of AstraZeneca’s $50 billion investment, first announced in July, and follows commitments to build a cell therapy manufacturing facility in Rockville, Maryland, a new drug substance manufacturing facility in Virginia, and to expand an existing manufacturing facility in Coppell, Texas.
AstraZeneca’s US workforce exceeds 25,000 people and supports more than 100,000 jobs overall across the country. In 2025, AstraZeneca created approximately $20 billion of overall value to the American economy.
AstraZeneca is a global, science-led biopharmaceutical company focusing on prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals. Its medicines are sold in over 125 countries.
Visit www.astrazeneca-us.com for more information.
Source: AstraZeneca
